Early- and mid-term outcomes following redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation
Key result
Redo SAVR after prior TAVI carries ~14% in-hospital mortality and poor two-year survival.
- n=28
Why the study?
Early- and mid-term outcomes following redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation required analysis.
What are the early- and mid-term outcomes of redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation?
Population
28 patients requiring redo SAVR after TAVI out of 5756 TAVI patients
Comparison
Redo SAVR for infective endocarditis vs non-infective endocarditis
Design
Retrospective single-centre analysis
Follow-up
24 months
Authors
Discussion
Loading...
Member takes
Implication
Provides early data on redo SAVR after TAVI failure; leaves open optimal valve selection and reintervention timing.
Study Design
Type
Observational (n=28)
Multicenter
No
Structured PICO
What are the early- and mid-term outcomes of redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation?
P
Population
28 patients who underwent redo surgical aortic valve replacement following a previous transcatheter aortic valve implantation between 2013 and 2020, followed for up to 24 months.
E
Exposure
Redo surgical aortic valve replacement (SAVR), either isolated or with additional cardiac surgical procedures.
O
Outcome
In-hospital mortality and mid-term survivalhard clinical
Redo surgical aortic valve replacement after TAVI is feasible but carries significant in-hospital mortality (14.3%) and reduced mid-term survival, particularly when indicated for infective endocarditis.
Cite This Study
Marin‐Cuartas et al. (2022) conducted an observational in Previous transcatheter aortic valve implantation requiring redo surgical aortic valve replacement (n=28). Redo surgical aortic valve replacement (SAVR) was evaluated on in-hospital mortality and mid-term survival. Redo surgical aortic valve replacement in patients with prior TAVI had an overall in-hospital mortality of 14.3% and an estimated 24-month survival of 48.0%.